-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
GE HealthCare reported mixed Q1 2026 results with revenue of $5.1B, up 7.4% Y/Y (+2.9% organic), but adjusted EBIT margin contracted 150 bps to 13.5% due to operational challenges and inflationary pressures. Adjusted EPS of $0.99 declined modestly from $1.01 in the prior year, impacted by discrete PDx supplier issues, rising memory chip, oil, and freight costs, plus ongoing tariff impacts. Segment performance was mixed, in our view, with Pharmaceutical Diagnostics leading growth at +21.7% reported (+9.7% organic), while Patient Care Solutions declined -6.5% with EBIT margins contracting 500 bps to just 1.4%. Management reduced full-year adjusted EPS guidance to $4.80-$5.00 (from $4.95-$5.15) while maintaining organic revenue growth expectations of 3.0%-4.0%, which we view as achievable. The company expects to offset more than half of inflation impact through pricing and cost mitigation efforts, though margin pressures are expected to persist through 2026, given current challenging market conditions.